2666-93-5

Basic information

• Product Name: methyl L-leucinate
• Synonyms: methyl L-leucinate;leucine methyl ester;L-METHYL-LEUCINE;(2S)-2-Amino-4-methylpentanoic acid methyl ester;(S)-2-Amino-4-methylvaleric acid methyl ester;Leucine methyl;L-Leucine methyl;(S)-Methyl 2-amino-4-methylpentanoate
• CAS NO: 2666-93-5
• Molecular Formula: C₇H₁₅NO₂
• Molecular Weight: 145.1995
• EINECS: 220-205-0
• Mol File: 2666-93-5.mol
• Article Data: 79

Chemical Properties

• Boiling Point: 169.2°Cat760mmHg
• Flash Point: 42.7°C
• Appearance: /
• Density: 0.955g/cm³
• Vapor Pressure: 1.56mmHg at 25°C
• Refractive Index: 1.435
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: methyl L-leucinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl L-leucinate(2666-93-5)
• EPA Substance Registry System: methyl L-leucinate(2666-93-5)

Safety Data

• Hazardous Substances Data: 2666-93-5(Hazardous Substances Data)

Usage

General Description

Methyl L-leucinate is a chemical compound classified as a leucine derivative. It is an ester formed by the reaction of L-leucine, an essential amino acid, with methanol. Methyl L-leucinate is used in various industries, including the food and fragrance industries, where it is valued for its fruity and floral aroma. As a flavoring agent, it is commonly added to food products and beverages to enhance their taste and odor. Additionally, it has applications in the production of perfumes and cosmetics, where it contributes to the formulation of pleasant scents. Overall, methyl L-leucinate plays a key role in adding desirable flavors and fragrances to a wide range of consumer products.

InChI:InChI=1/C7H15NO2/c1-5(2)4-6(8)7(9)10-3/h5-6H,4,8H2,1-3H3

Upstream product

• 61-90-5 L-leucine 
• 77-76-9 2,2-dimethoxy-propane 
• 18869-43-7 DL-leucine methyl ester 
• 625-53-6 ethyl-2-thiourea 
• 479201-62-2 (S)-2-((R)-2-Methanesulfonyloxy-propionylamino)-4-methyl-pentanoic acid methyl ester 
• 1222062-84-1 2-[(1-methoxycarbonyl-3-methylbutylamino)methylene]malonic acid diethyl ester 
• 139551-80-7 N^α-Fmoc-Leu-OMe 
• 110098-02-7 2-(2-Aza-bicyclo[2.2.1]hept-5-en-2-yl)-4-methyl-pentanoic acid methyl ester; hydrochloride 
• 35661-60-0 Fmoc-Leu-OH 
• 75-77-4 chloro-trimethyl-silane 
• 816-66-0 4-methyl-2-oxopentanoic acid 
• 1420845-94-8 6-hydroxymetatacarboline I 
• 186581-53-3 diazomethane 
• 14723-87-6 L-leucine phenylhydrazide 

Downstream Products

• 34576-15-3 N-(4-nitro-benzoyl)-L-leucine methyl ester 
• 1115-39-5 N-trifluoroacetyl methyl ester of (S)-leucine 
• 869-19-2 Glycyl-L-leucine 
• 17331-93-0 N-benzyloxycarbonylglycyl-L-leucine methyl ester 
• 112552-45-1 N-(N-benzyloxycarbonyl-L-γ-glutamyl)-L-leucine 
• 3017-50-3 N,N'-bis-(N-benzyloxycarbonyl-glycyl)-hydrazine 
• 18323-56-3 Z-(S)-Ala-(S)-Leu-NH₂ 
• 5289-88-3 N-(N^α-benzyloxycarbonyl-N^ω-nitro-L-arginyl)-L-leucine methyl ester 
• 118659-91-9 S-benzyl-N-benzyloxycarbonyl-cysteinyl=>tyrosyl=>leucine methyl ester 
• 3504-37-8 Cbz-L-Leu-L-Leu-OMe 
• 33104-49-3 N-^α-Z-L-glutaminyl-L-leucine methyl ester 
• 4818-10-4 N-(N^α.N^δ-bis-benzyloxycarbonyl-L-ornithyl)-L-leucine methyl ester 
• 55260-11-2 N-[N-(N-benzyloxycarbonyl-glycyl)-glycyl]-L-leucine methyl ester 
• 30033-84-2 N-(N^α-benzyloxycarbonyl-histidyl)-leucine methyl ester 

Relevant articles and documents

A convenient protocol for selective cleavage of 2-hydroxy acid amides. Application to semisynthesis of the cyclic heptapeptide aza HUN-7293.

A two-step protocol for the first chemoselective cleavage of 2-hydroxy acid amides has been developed. Mesylation of the model substrate 2-(hydroxypropionylamino)-4-methylpentanoic acid methyl ester (11) followed by treatment with N-ethylthiourea (13) all

New amino acid clubbed Schiff bases inhibit carbonic anhydrase II, α-glucosidase, and urease enzymes: in silico and in vitro

Combating pathological conditions related to hyperactivity of enzymes remains a formidable challenge for health. Small molecules therapy constitutes one of the means to circumvent the medical disorders resulting from enzyme hyperactivity. In this regard, we have synthesized structurally diverse amino acid hybrid Schiff bases (5a–5l and 10a–10k) and evaluated them for carbonic anhydrase II, α-glucosidase, and urease inhibitory potential. These new chemical scaffolds showed variable efficacies against the selected enzymes. The results indicated that compounds 5b (11.8 ± 1.33 μM), 10i (83.3 ± 1.13 μM), and 10f (88.2 ± 2.27 μM) are the most active scaffolds against carbonic anhydrase II, α-glucosidase, and urease, respectively. A structure–activity relationship revealed the most structural features contributing to the overall activities. Molecular docking suggested that these compounds possess excellent binding interactions with the active site residues of the targets by interacting through hydrogen bonding, π–π, and π–cation interactions.

SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES

The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to the solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

Synthesis and evaluation of antitumor activities of 4-selenopyrimidine derivatives

Pyrimidine antimetabolic agents are the essential drugs in treatment of various tumors. Novel synthesis and biological evaluation of the pyrimidine derivatives incorporating selenium element and amino acid carrier as potential antitumor agents have not been tried and studied. Based on the biological significance of pyrimidine structure, these two additional elemental fragments maybe enhance the antitumor effect and reduce toxic side effects of pyrimidine agents. The aim of this paper is to synthesis a series of 4-selenopyrimidine derivatives in order to find more potent lead compounds against cancer. In this study, 12 new 4-selenopyrimidine derivatives that are unstable in acidic solutions but very stable in alkaline and neutral solutions avoiding light were synthesized, and the antitumor activities on HepG2 cell lines of these compounds were evaluated by MTT assay. The results have shown that these compounds could reduce the proliferation of HepG2 cells in a dose-dependent fashion, and the inhibitory activity of compounds a6 was greater than that of positive control 5-fluorouracil (5-FU), the IC50 for a6 was 3.63 μM. In the comprehensive analysis of the structure–activity relationship, we could draw the antitumor effect of selenouracil derivatives is stronger than those of selenothymine derivatives. These results suggest that the substituent groups of selenium element and amino acid on the pyrimidine derivatives are vital for their antitumor activities on HepG2 cells.